Business
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference
Châtillon, France, May 5, 2025 DBV Technologies to Participate in the Citizens JMP Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025, at 11:00am ET, in New York, NY. A live webcast of the fireside chat can be accessed here, and will als
About this update from Dbv Technologies Sa
[{"type":"image","alt":"DBV Technologies S.A.","displaySize":"","headline":null,"caption":"DBV Technologies S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":157,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/06466da7ac8627e27b0291db4f69adde"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nRDNubmRBJgeAgXMmddvoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06466da7ac8627e27b0291db4f69adde","width":157,"height":157}},"lazy":false},{"type":"text","content":"Châtillon, France, May 5, 2025","length":30,"tagName":"p"},{"type":"text","content":"DBV Technologies to Participate in the Citizens JMP Life Sciences Conference","length":76,"tagName":"p"},{"type":"text","content":"DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025, at 11:00am ET, in New York, NY.","length":321,"tagName":"p"},{"type":"text","content":"A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/","length":197,"tagName":"p"},{"type":"text","content":"A replay will also be available on DBV Technologies’ website for 90 days after the event.","length":89,"tagName":"p"},{"type":"text","content":"About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-edu...